Recent research has uncovered the potential of minocycline, a tetracycline antibiotic, in modifying fear memory retention. A new study conducted by Yanfang Xia and colleagues, published in Translational Psychiatry, highlights how minocycline could play a role in treating anxiety and stress-related disorders. Highlights: Study Basis: The study was based on Pavlovian fear conditioning as a …
Patients with severe mental illnesses (SMI), such as schizophrenia and chronic depression, often face the challenge of managing weight gain and metabolic complications, side effects commonly associated with antipsychotics and antidepressants. These medications are known to induce increased appetite and weight gain, leading to long-term metabolic syndromes. Recent studies have evaluated into the role of …
Obsessive-compulsive disorder (OCD), a prevalent neuropsychiatric condition, presents significant treatment challenges due to its varied symptom patterns and poor response to traditional medications. Recent research has revealed a novel approach to treating OCD, focusing on the interplay between dopamine D2 receptor (D2R) agonists and proton pump inhibitors (PPIs). Highlights: OCD’s Complex Treatment Landscape: Traditional treatments …
Opioid Use Disorder (OUD) remains a significant public health crisis, with buprenorphine emerging as a key medication in its treatment. Approved by the FDA, buprenorphine works as a partial opioid agonist, helping reduce opioid use and improve treatment retention rates compared to placebo. Despite its effectiveness, challenges in patient retention and optimal treatment duration persist. …
In the complex and evolving field of neuroscience, the role of synaptic plasticity in psychiatric disorders has garnered significant attention. d-Cycloserine (DCS), a partial agonist of the N-methyl-D-aspartate receptor (NMDAR), emerges as a key player in potentially revolutionizing treatment approaches. Highlights: d-Cycloserine (DCS): Initially an antimicrobial agent, DCS is now known for its role as …
Recent advancements in neuropharmacology have brought to light S-CE-123, a dopamine transporter inhibitor showing remarkable promise in cognitive enhancement. Its emergence alongside R-modafinil, a well-studied compound with a similar target, paves the way for a fascinating comparative study. This duo of compounds, entwined in the complex dance of brain chemistry, offers a glimpse into the …
Alzheimer’s Disease (AD), a prevalent form of dementia, poses significant challenges for individuals and healthcare systems worldwide. Current treatments primarily offer symptomatic relief without altering the disease’s progression. However, emerging research suggests that caffeine, a widely consumed psychoactive substance, may have neuroprotective properties against AD. Highlights: Alzheimer’s Disease is the most common form of dementia, …